PBC and PSC

747-302

A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis (Intercept 747-302).

This is a phase 3b research study for patients with primary biliary cirrhosis age 18 years and older. Participants will remain on the study and continue to receive the study investigational medication or placebo until the study is completed unless they are removed or voluntarily end participation. It is estimated that patients will participate for a minimum of 6 years. During this time, participants will be evaluated by the study team approximately every three months.

 

GS-US-427-4024

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis (GS-US-427-4024)

This is a phase 2 research study for people with primary biliary cholangitis (PBC) age 18-70 years. During the blinded study phase, participants will receive the study investigational medication and/or placebo for approximately 12 weeks unless they are removed or voluntarily end participation. During this time, participants will be evaluated by the study team approximately every 1-4 weeks. After completing the blinded treatment phase, participants may be eligible to participate in a 96 week open-label extension.

 

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest:

ATTENTION: This form is not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Calls of this nature will not be answered by email and should be directed to 612-871-1145. In the event of a medical emergency, dial 911. Emails are monitored Monday through Friday during regular business hours.